These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 18208868)

  • 1. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble HLA-G molecules are released as HLA-G5 and not as soluble HLA-G1 isoforms in CSF of patients with relapsing-remitting multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Caniatti ML; Baldi E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2007 Dec; 192(1-2):219-25. PubMed ID: 17997167
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
    Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Paolino E; Tola MR; Granieri E; Baricordi OR
    Mult Scler; 2006 Feb; 12(1):2-12. PubMed ID: 16459714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential role of soluble human leukocyte antigen-G molecules in multiple sclerosis.
    Fainardi E; Rizzo R; Castellazzi M; Stignani M; Granieri E; Baricordi OR
    Hum Immunol; 2009 Dec; 70(12):981-7. PubMed ID: 19651179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis.
    Castellazzi M; Tamborino C; Cani A; Negri E; Baldi E; Seraceni S; Tola MR; Granieri E; Contini C; Fainardi E
    Mult Scler; 2010 Jul; 16(7):883-7. PubMed ID: 20483883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
    Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
    Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
    Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
    J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Tamborino C; Trentini A; Manfrinato MC; Baldi E; Tola MR; Dallocchio F; Granieri E; Bellini T
    Mult Scler; 2009 May; 15(5):547-54. PubMed ID: 19318509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrathecal soluble HLA-E correlates with disease activity in patients with multiple sclerosis and may cooperate with soluble HLA-G in the resolution of neuroinflammation.
    Morandi F; Venturi C; Rizzo R; Castellazzi M; Baldi E; Caniatti ML; Tola MR; Granieri E; Fainardi E; Uccelli A; Pistoia V
    J Neuroimmune Pharmacol; 2013 Sep; 8(4):944-55. PubMed ID: 23625177
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules.
    Fainardi E; Granieri E; Tola MR; Melchiorri L; Vaghi L; Rizzo R; Castellazzi M; Ceruti S; Paolino E; Baricordi OR
    J Neuroimmunol; 2002 Dec; 133(1-2):151-9. PubMed ID: 12446018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble HLA-A,-B,-C and -G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation.
    Contini P; Ghio M; Poggi A; Filaci G; Indiveri F; Ferrone S; Puppo F
    Eur J Immunol; 2003 Jan; 33(1):125-34. PubMed ID: 12594841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of sFas indicates apoptosis in human herpes simplex encephalitis.
    Sabri F; Granath F; Hjalmarsson A; Aurelius E; Sköldenberg B
    J Neuroimmunol; 2006 Feb; 171(1-2):171-6. PubMed ID: 16325272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis.
    Fainardi E; Castellazzi M; Bellini T; Manfrinato MC; Baldi E; Casetta I; Paolino E; Granieri E; Dallocchio F
    Mult Scler; 2006 Jun; 12(3):294-301. PubMed ID: 16764342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble HLA-G in rheumatoid arthritis.
    Verbruggen LA; Rebmann V; Demanet C; De Cock S; Grosse-Wilde H
    Hum Immunol; 2006 Aug; 67(8):561-7. PubMed ID: 16916651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of HLA-G 14bp deletion/insertion and +3142C>G polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis.
    Rizzo R; Bortolotti D; Fredj NB; Rotola A; Cura F; Castellazzi M; Tamborino C; Seraceni S; Baldi E; Melchiorri L; Tola MR; Granieri E; Baricordi OR; Fainardi E
    Hum Immunol; 2012 Nov; 73(11):1140-6. PubMed ID: 22922127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
    Wiendl H; Feger U; Mittelbronn M; Jack C; Schreiner B; Stadelmann C; Antel J; Brueck W; Meyermann R; Bar-Or A; Kieseier BC; Weller M
    Brain; 2005 Nov; 128(Pt 11):2689-704. PubMed ID: 16123145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased production of human leukocyte antigen G molecules in sinonasal polyposis.
    Malagutti N; Aimoni C; Balboni A; Stignani M; Melchiorri L; Borin M; Pastore A; Rizzo R; Baricordi OR
    Am J Rhinol; 2008; 22(5):468-73. PubMed ID: 18954504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Level of sFas/APO 1 in serum and cerebrospinal fluid in multiple sclerosis.
    Mahovic D; Petravic D; Petelin Z; Zurak N; Horvat G; Hajnsek S
    Clin Neurol Neurosurg; 2004 Jun; 106(3):230-2. PubMed ID: 15177773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progressive multifocal leukoencephalopathy and relapsing-remitting multiple sclerosis: a comparative study.
    Boster A; Hreha S; Berger JR; Bao F; Penmesta R; Tselis A; Endress C; Zak I; Perumal J; Caon C; Vazquez J; Tyler KL; Racke MK; Millis S; Khan O
    Arch Neurol; 2009 May; 66(5):593-9. PubMed ID: 19433659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.